Literature DB >> 18549248

Disulfide connectivity of human immunoglobulin G2 structural isoforms.

Theresa Martinez1, Amy Guo, Martin J Allen, Mei Han, Danielle Pace, Jay Jones, Ron Gillespie, Randal R Ketchem, Yuling Zhang, Alain Balland.   

Abstract

In this communication we present the detailed disulfide structure of IgG2 molecules. The consensus structural model of human IgGs represents the hinge region positioned as a flexible linker connecting structurally isolated Fc and Fab domains. IgG2 molecules are organized differently from that model and exhibit multiple structural isoforms composed of (heavy chain-light chain-hinge) covalent complexes. We describe the precise connection of all the disulfide bridges and show that the IgG2 C H1 and C-terminal C L cysteine residues are either linked to each other or to the two upper hinge cysteine residues specific to the IgG2 subclass. A defined arrangement of these disulfide bridges is unique to each isoform. Mutation of a single cysteine residue in the hinge region eliminates these natural complexes. These results show that IgG2 structure is significantly different from the conventionally accepted immunoglobulin structural model and may help to explain some of the unique biological activity attributed only to this subclass.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549248     DOI: 10.1021/bi800576c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.

Authors:  Shirley J Peters; C Mark Smales; Alistair J Henry; Paul E Stephens; Shauna West; David P Humphreys
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

2.  Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.

Authors:  Takahiko Ito; Kouhei Tsumoto
Journal:  Protein Sci       Date:  2013-09-30       Impact factor: 6.725

3.  Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.

Authors:  Xiaoling Wang; Tapan K Das; Satish K Singh; Sandeep Kumar
Journal:  MAbs       Date:  2009-05-29       Impact factor: 5.857

Review 4.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

5.  6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors:  Alain Beck; Thierry Wurch; Janice M Reichert
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

6.  Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains.

Authors:  Jun Zhao; Ruth Nussinov; Buyong Ma
Journal:  Protein Eng Des Sel       Date:  2016-11-29       Impact factor: 1.650

Review 7.  Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies.

Authors:  Yi Du; Alison Walsh; Robin Ehrick; Wei Xu; Kimberly May; Hongcheng Liu
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

8.  Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations.

Authors:  Xiaoling Wang; Sandeep Kumar; Satish K Singh
Journal:  Pharm Res       Date:  2011-06-14       Impact factor: 4.200

9.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage.

Authors:  Boxu Yan; Zac Yates; Alain Balland; Gerd R Kleemann
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.